Results Snapshot
Figures in Cr
Standalone - Profit And Loss Results
Mar'25
Mar'24
Mar'23
Mar'22
Mar'21
Mar'20
Profit And Loss Analysis Highlights
Net Sales
YoY Growth in year ended Mar 2025 is 32.48% vs 29.17% in Mar 2024
Operating Profit (PBDIT) excl Other Income
YoY Growth in year ended Mar 2025 is 37.69% vs 11.71% in Mar 2024
Interest
YoY Growth in year ended Mar 2025 is 21.67% vs 90.48% in Mar 2024
Profit After Tax
YoY Growth in year ended Mar 2025 is -28.34% vs 62.66% in Mar 2024
Compare Profit and Loss Results of Astrazeneca Phar
Figures in Cr
standalone - Profit And Loss Results
Change(INR)
Change(%)
No of Months
12
12
Operating Income
1,716.00
1,402.00
314.00
22.40%
Less :Inter divisional transfers
0.00
0.00
0.00
0%
Less: Excise
0.00
0.00
0.00
0%
Net Sales
1,716.00
1,402.00
314.00
22.40%
Expenditure (Ex Depriciation)
Stock Adjustments
-332.00
-46.00
-286.00
-621.74%
Raw Materials Consumed
1,295.00
482.00
813.00
168.67%
Power & Fuel Cost
5.00
75.00
-70.00
-93.33%
Employee Cost
257.00
262.00
-5.00
-1.91%
Operating Expenses
18.00
71.00
-53.00
-74.65%
General and Administration Expenses
-1.00
-1.00
0.00
0.00%
Selling and Distribution Expenses
93.00
57.00
36.00
63.16%
Cost of Software developments
0.00
0.00
0.00
0%
Miscellaneous Expenses
13.00
78.00
-65.00
-83.33%
Expenses Capitalised
0.00
0.00
0.00
0%
Total Expenditure
1,462.00
1,102.00
360.00
32.67%
Operating Profit (PBDIT) excl Other Income
253.00
300.00
-47.00
-15.67%
Other Income
40.00
55.00
-15.00
-27.27%
Operating Profit (PBDIT)
294.00
355.00
-61.00
-17.18%
Interest
1.00
199.00
-198.00
-99.50%
Profit before Depriciation and Tax
293.00
156.00
137.00
87.82%
Depreciation
39.00
168.00
-129.00
-76.79%
Profit Before Taxation & Exceptional Items
253.00
-12.00
265.00
2,208.33%
Exceptional Income / Expenses
0.00
0.00
0.00
0%
Profit Before Tax
156.00
-12.00
168.00
1,400.00%
Provision for Tax
40.00
0.00
40.00
0%
Profit After Tax
115.00
-12.00
127.00
1,058.33%
Extraordinary Items
0.00
0.00
0.00
0%
Adj to Profit After Tax
0.00
0.00
0.00
0%
Profit Balance B/F
578.00
-890.00
1,468.00
164.94%
Profit Available for appropriations
693.00
-902.00
1,595.00
176.83%
Appropriations
693.00
-902.00
1,595.00
176.83%
Equity Dividend (%)
1600%
0%
1,600.00
Earnings Per Share
46.3
-0.76
47.06
6,192.11%
Profit And Loss - Net Sales
Net Sales 1,716.29 Cr
in Mar 2025Figures in Cr
YoY Growth in year ended Mar 2025 is 32.48% vs 29.17% in Mar 2024
Profit And Loss - Operating Profit (PBDIT)
Operating Profit (PBDIT) 253.97 Cr
in Mar 2025Figures in Cr
YoY Growth in year ended Mar 2025 is 37.69% vs 11.71% in Mar 2024
Profit And Loss - Interest
Interest 1.46 Cr
in Mar 2025Figures in Cr
YoY Growth in year ended Mar 2025 is 21.67% vs 90.48% in Mar 2024
Profit And Loss - Profit After Tax
Profit After Tax 115.74 Cr
in Mar 2025Figures in Cr
YoY Growth in year ended Mar 2025 is -28.34% vs 62.66% in Mar 2024






